Biotechnology

Avita Medical

Avita Medical released FY2025 Q3 earnings on November 6 After-Market EST, actual revenue USD 17.06 M (forecast USD 18.21 M), actual EPS USD -0.4644 (forecast USD -0.3155)

Avita Medical released FY2025 9 Months earnings on November 6 After-Market (EST), actual revenue USD 53.99 M, actual EPS USD -1.3685

Avita Medical to Release FY2025 Q3 Earnings on November 6 After-Market (EST), Forecast Revenue USD 17.96 M, EPS USD -0.311

Analyst Zimmerman Recommends Buy for Avita Medical

Avita Medical released FY2025 Q2 earnings on August 8 After-Market EST, actual revenue USD 18.42 M (forecast USD 22.36 M), actual EPS USD -0.3762 (forecast USD -0.2577)

Avita Medical released FY2025 Semi-Annual earnings on August 8 After-Market EST, actual revenue USD 36.93 M, actual EPS USD -0.9007

Avita Medical to Release FY2025 Q2 Earnings on August 7 After-Market EST, Forecast Revenue USD 22.54 M, EPS USD -0.2597

Avita Medical's Recell System Significantly Reduces Burn Patients' Hospital Stay

D. Boral Capital Maintains AVITA Medical Buy Rating

AVITA Medical Releases Preliminary Clinical Study Results for Cohealyx

AVITA Medical's RECELL Platform Wins Best New Technology Solution Award 2025

AVITA Medical Bearish Positions Increase

Delta Investment Management LLC increased AVITA Medical stock holdings

Avita Medical Inc. Updates Bylaws to Reflect New Legal Standards

Avita Medical Reports Q1 EPS Loss Narrowing but Exceeding Estimates

Avita Medical released FY2025 Q1 earnings on May 8 After-Market EST, actual revenue USD 18.51 M (forecast USD 21.32 M), actual EPS USD -0.5278 (forecast USD -0.3613)

Avita Medical to release FY2025 Q1 earnings on May 8 After-Market EST, forecast revenue USD 20.85 M, EPS USD -0.3613

AVITA Medical to Present Clinical Data on Wound Care Technologies at 2025 ABA Annual Meeting

Analysts' Evaluation and Target Price Changes for AVITA Medical

AVITA Medical Signs New Manufacturing Agreement with Stedical Scientific

AdvisorShares MSOS 2x Daily ETF

cbdMD

Tryhard

Roundhill Cannabis ETF

Neo-Concept

Amplify Seymour Cannabis ETF

AdvisorShares Pure US Cannabis ETF

Canopy Growth

RYTHM

Tilray Brands

Adma Biologics

Kiniksa Pharmaceuticals

Stoke Therapeutics

Rigel Pharma

OpGen

Vertex Pharma

Regeneron Pharma

Argenx

Alnylam Pharma

Beigene

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Revenue

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap